Kynurenic Acid

Your body breaks down tryptophan, an amino acid you get from food, down two main roads. One road makes serotonin, which shapes mood and sleep. The other road, called the kynurenine pathway, ramps up when your immune system activates or your metabolism shifts under stress. KYNA (kynurenic acid) is one of the key products of that second road, and a urine test gives a non-invasive window into how busy that pathway is.

Why pay attention to a molecule most people have never heard of? Because the balance of products along this pathway has been linked, in human studies, to depression, migraine, autism, Alzheimer's disease, kidney disease, chronic pain, and infection severity. KYNA sits on what researchers describe as the more protective branch of the pathway, and watching how it moves in your urine can tell you something about a slice of your biology that no standard lab panel captures.

What This Test Actually Measures

This is a urine test. It quantifies KYNA that your kidneys have filtered or secreted into the urine. That is biologically different from KYNA measured in blood, which captures what is circulating before excretion, and from KYNA measured in cerebrospinal fluid, which sits closer to the brain. KYNA itself does not cross the blood-brain barrier well, so what shows up in urine mostly reflects production in peripheral tissues, including immune cells, the gut, and other organs.

Because the kynurenine pathway is regulated by an enzyme called IDO (indoleamine 2,3-dioxygenase) that switches on during inflammation, urinary kynurenines also serve as an indirect readout of immune activation. KYNA specifically sits on the branch produced more in astrocytes, the support cells of the brain, while a different branch leading to quinolinic acid is more active in immune cells like microglia and macrophages. The split between these two branches matters because they have opposite tendencies in the brain, one calming and one excitatory.

Why This Marker Is Still Exploratory

Urinary KYNA is a research-grade biomarker. There are no universally standardized reference ranges, no consensus cutpoints for what counts as high or low, and no professional guidelines recommending routine testing in asymptomatic adults. The science is moving quickly, but it has not yet matured into the kind of clear-cut tool that LDL cholesterol or HbA1c (a measure of average blood sugar) represents.

That does not mean the test is useless. It means the value comes from establishing your own baseline, watching how it moves with changes in your diet, lifestyle, or health, and treating any single reading as part of a longer story rather than a diagnosis. Frame it as exploratory data that adds context, not a verdict.

Mood, Diet, and Mental Health

In a study of 169 young adults, people who ate more of a Western-style diet (high in processed foods, refined sugars, and saturated fat) had lower urinary KYNA. Lower urinary KYNA in turn tracked with more depressive symptoms, and this link held even after accounting for two common inflammation markers in urine. That suggests KYNA may carry information about mood biology beyond what standard inflammation tests reveal.

In people with constipation-predominant irritable bowel syndrome, the picture flips: higher urinary kynurenine, quinolinic acid, and KYNA all correlated with worse depression scores. The takeaway is not that KYNA is always good or always bad. It is that the balance between KYNA and its more excitotoxic counterpart, quinolinic acid, shifts with both the gut and the brain in ways that ordinary mood questionnaires cannot see.

Reconciling a Mixed Picture

You may have noticed that low urinary KYNA links to depression in one context and high urinary KYNA links to depression in another. This is not a contradiction. KYNA is best thought of as a phenotype indicator, not a simple good-or-bad number. What matters is the pattern: how KYNA stacks against kynurenine, quinolinic acid, and tryptophan itself, and what the rest of the clinical picture looks like. A standalone KYNA reading without that context is hard to interpret, which is exactly why tracking your own trajectory over time tends to be more useful than chasing a single ideal value.

Migraine and Headache

In a study of people with episodic migraine, urinary KYNA was lower than in controls, while kynurenine and quinolinic acid were higher. The ratios between these metabolites (KYNA/kynurenine and KYNA/quinolinic acid) were altered in ways that tracked with how disabling the migraine attacks were. Researchers are exploring whether these patterns could help characterize migraine biology beyond what a typical clinical history reveals.

Alzheimer's Disease and Cognition

In a study spanning hundreds of participants across the spectrum from healthy controls through mild cognitive impairment to Alzheimer's disease, urinary KYNA, tryptophan, and a related metabolite called xanthurenic acid were all lower in Alzheimer's. The ratio of kynurenine to tryptophan in urine was higher, suggesting more tryptophan was being pushed into the kynurenine pathway, likely from inflammation-driven IDO activity. Higher kynurenine-to-tryptophan ratios tracked with worse cognitive status.

Autism Spectrum

A urinary metabolomics study of young Italian children with autism found a shift in tryptophan metabolism: more was being converted to quinolinic and xanthurenic acids, at the expense of KYNA and melatonin. This pattern suggests the protective branch of the pathway was suppressed relative to the more excitatory branch, an imbalance that may relate to comorbidities like seizures, sleep disorders, and gastrointestinal symptoms commonly reported in autism.

Kidney Disease

Kidney disease changes the picture because the kidneys themselves clear KYNA from circulation. In a CRIC study analysis of adults with chronic kidney disease, lower kidney clearance of secretory solutes including KYNA was associated with faster CKD (chronic kidney disease) progression and higher mortality, independent of eGFR (estimated glomerular filtration rate) and albuminuria. In other words, the kidneys' ability to handle KYNA seems to provide information about kidney health that standard filtration tests miss.

In a large study of patients with type 2 diabetes, higher levels of tryptophan, KYNA, and xanthurenic acid in plasma were tied to slower kidney function decline, while a higher kynurenine-to-tryptophan ratio predicted faster decline. A targeted metabolomics study of 119 people found urinary KYNA contributed to a panel of markers that distinguished early CKD stages from healthy controls.

COVID-19 and Acute Inflammation

In a study of hospitalized COVID-19 patients, urinary kynurenines including kynurenine and a related metabolite called 3-hydroxykynurenine rose sharply with disease severity. The increases tracked with C-reactive protein (a standard inflammation marker) and independently predicted death or need for mechanical ventilation, even after accounting for kidney function. A larger cohort found that kynurenines showed the highest fold change in deteriorating patients, with the accumulation tied to disrupted NAD+ and SIRT1 signaling, which are core energy and longevity pathways.

Chronic Pain

In a study of active-duty service members with chronic pain, a urine metabolite pain indicator that included KYNA correlated with fatigue, anxiety, depression, physical function, and the overall impact of pain on daily life. KYNA showed some of the strongest individual associations in that panel. A follow-up analysis after pain treatment found KYNA continued to track with sleep-related impairment, suggesting it captures something about pain biology that pain scores alone do not.

Tracking Your Trend

A single urinary KYNA reading is hard to act on in isolation. Levels shift with diet, kidney function, infection, and the broader balance of the kynurenine pathway. The science has not yet established firm cutpoints to compare yourself against. What it has established is that the pathway responds to interventions, and that the direction your number moves matters more than the absolute value.

A reasonable cadence is to establish a baseline now, retest after 3 to 6 months if you are making meaningful changes to your diet, exercise routine, gut health, or supplement regimen, and then check at least annually thereafter. If you retest, try to control conditions: same time of day, similar diet in the day or two before, and no recent acute illness or intense exercise sessions, which can transiently shift kynurenine pathway activity.

When Results Can Be Misleading

Urinary KYNA can be distorted by factors that have nothing to do with your underlying biology. Lead with these when interpreting any single reading:

• Recent infection or acute illness: systemic inflammation activates the IDO enzyme and pushes more tryptophan down the kynurenine pathway, raising several kynurenines for days to weeks
• Kidney function changes: because the kidneys handle KYNA clearance, shifts in glomerular filtration or tubular secretion can alter urinary KYNA without reflecting a change in production
• Pre-test diet: a recent shift toward a more Western-style diet has been linked to lower urinary KYNA, while extended fasting has been shown to alter kynurenine excretion patterns
• Recent intense exercise: acute heavy exertion modulates kynurenine pathway flux in the short term and may produce a reading that does not reflect your usual state

Decision Pathway for Out-of-Pattern Results

If your KYNA result looks unexpected, the next step is rarely to act on it alone. Retest first under more controlled conditions. Then look at the result alongside companion markers that anchor interpretation: a standard inflammation marker like hs-CRP (high-sensitivity C-reactive protein), kidney function via eGFR and cystatin C, and a metabolic readout like fasting glucose, insulin, or HbA1c. If multiple markers point the same direction (say, elevated inflammation plus altered kynurenine pathway activity plus rising glucose), that pattern is more actionable than KYNA alone.

If you have a known condition this pathway intersects with (chronic kidney disease, autoimmune disease, depression that is not responding to treatment, or recurrent migraine), the most useful next step is usually a conversation with a specialist familiar with metabolomic markers: a nephrologist for kidney patterns, a neurologist for migraine or cognitive concerns, or a psychiatrist for mood-related findings. KYNA fits best as one input into a broader workup, not as a standalone trigger for treatment changes.